Fingolimod versus High Dose Interferon Beta-1a in Multiple Sclerosis: A Randomized Clinical Trial
محل انتشار: علوم اعصاب کاسپین، دوره: 3، شماره: 8
سال انتشار: 1396
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 342
فایل این مقاله در 8 صفحه با فرمت PDF قابل دریافت می باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_CJNS-3-8_001
تاریخ نمایه سازی: 18 اسفند 1397
چکیده مقاله:
Background: High dose Interferon Beta and Fingolimod are efficient inMultiple Sclerosis.Objectives: Comparison the efficacy of these two drugs in patients withtreatment failure on low dose interferon beta.Materials and Methods: The MS patients (McDonald criteria 2010) with thehistory of unbeneficial treatment on low dose interferon beta participated in thisrandomized clinical trial in MS clinic in a university hospital in Isfahan from2014 to 2016. They were randomly assigned to two groups receiving high doseinterferon beta-1a (Recigen) or Fingolimod. The number of relapses, EDSS,and Magnetic Resonance Imaging (MRI) findings were evaluated at thebeginning, 3, 9, 12, and 18 months after intervention. The t-test and MannWhitney U test and ANCOVA in SPSS version 20 were used.Results: A total of 120 MS patients with the mean age of 38.07±9.0 yearsincluded in this study and 35.8% of whom were males.The mean EDSS was lower in Fingolimod group from the 9th month to the endof intervention (1.80±1.05 vs. 2.17±0.95 in the 9th month and 1.95±0.92 vs.2.30±0.96 in 18th month). The mean number of relapses was lower inFinglimod group significantly in the 12th and 18th months (0.91±0.76 vs.1.27±0.77 in the 12th and 0.6±0.55 vs 1.0±0.71 in the 18th month). The meanvalues of new T2 lesions (1.00 vs. 1.47) and gadolinium enhancing lesions(0.467 vs. 0.817) were lower in Fingolimod group at the end of the study.Conclusion: Both treatments were beneficial with a significant superiority ofFingolimod.
کلیدواژه ها:
نویسندگان
Masoud Etemadifar
MD, Professor of Neurology, Department of neurology, Isfahan University of Medical Sciences, Isfahan, Iran
Pedram Moeini
MD, Resident of Neurology, Department of neurology, Isfahan University of Medical Sciences, Isfahan, Iran
Seyed-Massoud Nabavi
MD, Associate Professor of Neurology, Shahed University of Medical Sciences, Tehran, Iran- Multiple Sclerosis Fellow, Stem Cell Biology and Technology, Royan Institute, Tehran, Iran